6. パーキンソン病
[臨床試験数:2,123,薬物数:2,046(DrugBank:324),標的遺伝子数:183,標的パスウェイ数:198]
Searched query = "Parkinson disease"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT00111982 (ClinicalTrials.gov) | December 2003 | 27/5/2005 | Trial of Extended Treatment With Liatermin (r-metHuGDNF) Administered by Continuous Intraputaminal (IPu)Infusion to Subjects With Idiopathic Parkinson's Disease Who Have Completed a Previous Trial of Liatermin | Multi-Center, Open-Label Trial of Extended Treatment With Liatermin (r-metHuGDNF) Administered by Continuous Intraputaminal (IPu) Infusion to Subjects With Idiopathic Parkinson's Disease Who Have Completed a Previous Trial of Liatermin (Protocol 20020168) | Parkinson's Disease | Biological: Liatermin | Amgen | Medtronic | Completed | 35 Years | 70 Years | Both | 34 | Phase 1;Phase 2 | United States |
2 | NCT00115427 (ClinicalTrials.gov) | March 2003 | 22/6/2005 | Study of Liatermin (r-metHuGDNF) Administered by Bilateral Intraputaminal (IPu) Infusion to Subjects With Idiopathic Parkinson's Disease | Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Trial of Liatermin (r-metHuGDNF) Administered by Bilateral Intraputaminal (IPu) Infusion to Subjects With Idiopathic Parkinson's Disease | Idiopathic Parkinson's Disease | Drug: Liatermin (r-metHuGDNF) | Amgen | NULL | Completed | 35 Years | 70 Years | Both | Phase 1 | United States | |
3 | NCT00006488 (ClinicalTrials.gov) | October 2000 | 8/11/2000 | Continuously Infused Intracerebral (IC) Recombinant-Methionyl Human Glial Cell Line-Derived Neurotrophic Factor (r-metHuGDNF) for the Treatment of Idiopathic Parkinson's Disease | Parkinson Disease | Drug: recombinant-methionyl human glial cell line-derived neurotrophic factor | National Center for Research Resources (NCRR) | NULL | Completed | 18 Years | 75 Years | Both | Phase 1 | United States |